Use of Phenoxybenzamine [PBZ] IV to Assist High Flow Low Pressure Perfusion [HFLPP] on Cardio-pulmonary Bypass
Status:
Terminated
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
Cardiopulmonary bypass [CPB] in small size bodies can result in decreased peripheral
perfusion. This results in anaerobic metabolism as evidenced by lactic acidosis. High flow
perfusion results in systemic hypertension which is accentuated by moderate hypothermia
commonly used during cardiopulmonary bypass. Phenoxybenzamine [PBZ] is an arteriolar
vasodilator that acts by irreversibly blocking the alpha adrenergic receptors. It causes
vasodilatation allowing high flow, low pressure CPB. It has been used extensively outside US
in Canada, Europe and Australia. In the US oral PBZ is FDA approved, whereas intravenous PBZ
is only available as an investigational drug